This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

New Biomarkers Evaluating Ovarian Cancer

This study has been completed.
Information provided by (Responsible Party):
Fujirebio Diagnostics, Inc. Identifier:
First received: November 3, 2011
Last updated: August 4, 2014
Last verified: August 2014
The purpose of this study is to evaluate new biomarkers for patients presenting to a physician for surgery to remove a mass in their pelvis and to continue to evaluate these types of patients using the ROMA algorithm for post-market benefits.

Adnexal Mass

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass

Resource links provided by NLM:

Further study details as provided by Fujirebio Diagnostics, Inc.:

Primary Outcome Measures:
  • Evaluate novel biomarkers for patients with an adnexal mass [ Time Frame: observational studies ]

Enrollment: 280
Study Start Date: December 2011
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women with an adnexal mass, presenting to a general surgeon or obstetrician/ gynecologist at a general or specialty center within the United States, for whom a decision to proceed with surgery to remove the mass has been made.

Inclusion Criteria:

  • Female, age 18 years or older
  • Adnexal mass present documented by imaging
  • Scheduled to undergo surgery based on a finding of adnexal mass
  • Able and willing to provide Informed Consent

Exclusion Criteria:

  • Previous history of ovarian cancer
  • Previous history of bilateral oophorectomy
  • Currently known to be pregnant
  • Unable to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01466049

United States, North Carolina
New Hanover Regional Medical Center
Wilmington, North Carolina, United States, 28402
United States, Oklahoma
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73110
Sponsors and Collaborators
Fujirebio Diagnostics, Inc.
Study Director: Diana Dickson Fujirebio Diagnostics, Inc.
  More Information

Responsible Party: Fujirebio Diagnostics, Inc. Identifier: NCT01466049     History of Changes
Other Study ID Numbers: FDI-35
Study First Received: November 3, 2011
Last Updated: August 4, 2014

Keywords provided by Fujirebio Diagnostics, Inc.:
Ovarian Cancer
Adnexal Mass
Pelvic Mass

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders processed this record on August 18, 2017